KANEKA
19.1.2023 04:57:38 CET | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), a wholly owned group company in Europe. We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118006042/en/
Kaneka Eurogentec S.A. building (Photo: Business Wire)
mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide*6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.
*1. |
GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards. |
*2. |
mRNA: An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics. |
*3. |
CDMO: Contract Development and Manufacturing Organization. |
*4. |
Food and Drug Administration (FDA): US governmental agency dealing with approval and supervision of violation of products which may be used by consumers in their daily life such as pharmaceutical products, cosmetics, medical devices, veterinary drugs and toys. |
*5. |
plasmid DNA: A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division. |
|
It is conventionally used in processes for producing biopharmaceuticals such as therapeutic proteins and has been applied to genetic medicines and vaccines in recent years. |
*6. |
Oligonucleotide: Short polymeric sequences of nucleotides (RNA or DNA). It is used as drug substance of nucleic acid therapeutics. |
[General description of Kaneka Eurogentec S.A.]
Headquarters: Liège, Belgium
President: Lieven Janssens
Description of business: Manufacturing and sales of proteins, nucleic acids and peptides for medicinal, diagnostic and basic research uses
Established: 1985
Capital: 31 million euros
URL: http://www.eurogentec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Charted Launches ERP-Native E-invoicing Across EMEA1.9.2026 14:30:00 CEST | Press release
Expansion will bring Charted E-invoicing across Europe, supporting accounts payable operations with a fully compliant invoicing process that remains embedded inside their ERP Charted, a leading accounts payable automation software and ERP services provider, today announced the expansion of Charted E-invoicing to support multiple countries spanning Europe, including Germany, France, Norway, Sweden, the Netherlands, Denmark and Finland. Further expansion to Italy, Romania, and Poland, will take place by the end of the quarter. These countries follow the official launch of Charted E-invoicing in Belgium, in May 2026. This expansion is designed to cement Charted support for users across EMEA, ensuring companies based in the region transacting on the PEPPOL network can remain compliant while keeping their accounts payable processes embedded inside their ERP. Charted E-invoicing works as a capability within Charted Invoice AI, to receive electronic invoices directly into the AP inbox, keepin
Riskified Expands its Risk Intelligence Platform with ARIA1.9.2026 14:00:00 CEST | Press release
AI Risk Intelligence Analyst (ARIA) gives fraud teams instant answers from their order data, helping them investigate patterns, drill into trends, and act on insights directly within the Riskified Control Center Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today expanded its risk intelligence platform with ARIA (AI Risk Intelligence Analyst), a conversational AI capability built directly into the Riskified Control Center. Fraud teams today have access to vast amounts of data, but solving urgent business questions often still requires exporting files, building reports, or waiting for additional analysis. ARIA changes that by letting merchants ask questions in natural language and get answers in seconds, complete with charts and tables that support the analysis. With direct access to Riskified metrics and their own business-specific reporting logic, ARIA can investigate and quickly answer a wide range of questions within an existing workflow
Vasion® Unlocks Windows PCs on Snapdragon Adoption with Native, Driverless Printing1.9.2026 14:00:00 CEST | Press release
Eliminating One of the Last Barriers to Enterprise Windows Modernization Vasion is removing a critical barrier to modern Windows device adoption with native, driverless printing for PCs powered by Snapdragon® compute processors. The Vasion Spring 2026 release delivers a seamless, cloud-native print experience, eliminating the need for printer drivers, emulation, or parallel print environments. The collaboration with Qualcomm Technologies combines the PC ecosystem reach of Snapdragon with Vasion's print automation expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901581087/en/ Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol (IPP) driverless printing support, enabling IT teams to modernize device fleets without disrupting operations or rearchitecting existing environments. Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol
Perma-Pipe and Welspun Announce Memorandum of Understanding to Establish Pipe Manufacturing and Coating Facilities in Jordan1.9.2026 14:00:00 CEST | Press release
Strategic Partnership to Establish Integrated Pipe Manufacturing and Coating Capabilities to Support Water, Oil & Gas, and Infrastructure Projects in Jordan and the Levant Region. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a global leader in engineered pipe solutions specialising in anti-corrosion coatings, insulation solutions, containment systems, custom fabrication and leak detection, today announced that it has signed, together with Welspun Corp Limited (“Welspun”), a Memorandum of Understanding (“MOU”) with the developers of Jordan’s National Water Carrier Project and the Government of the Hashemite Kingdom of Jordan to advance the development of pipe manufacturing and advanced coating facilities in Jordan. The parties intend to establish a joint venture to support the development and operation of these facilities. Transaction Description Under the terms of the MOU, Perma-Pipe and Welspun have partnered to establish an integrated pipe m
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom